A5079820450- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Malaria Research and Control
- Viral Infections and Outbreaks Research
- Virology and Viral Diseases
- Respiratory viral infections research
- COVID-19 epidemiological studies
- Vaccine Coverage and Hesitancy
- HIV Research and Treatment
- Insect symbiosis and bacterial influences
- Vibrio bacteria research studies
- Influenza Virus Research Studies
- Zoonotic diseases and public health
- SARS-CoV-2 and COVID-19 Research
- Vector-borne infectious diseases
- Travel-related health issues
- vaccines and immunoinformatics approaches
- Global Maternal and Child Health
- Dengue and Mosquito Control Research
- Computational Drug Discovery Methods
- Heparin-Induced Thrombocytopenia and Thrombosis
- Viral gastroenteritis research and epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Parvovirus B19 Infection Studies
- Hepatitis Viruses Studies and Epidemiology
Johns Hopkins University
2015-2024
Johns Hopkins Medicine
2023
Icahn School of Medicine at Mount Sinai
2022
University of Rochester
2021
Unity Health System
2021
Columbia University
2021
University of Maryland, Baltimore
2021
Walter Reed Army Institute of Research
2021
New York University
2021
Bloomberg (United States)
2017-2018
Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) proposed. In US, Ad26.COV2.S COVID-19 (Janssen/Johnson & Johnson), human vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million...
Background Pfs25 and Pvs25, surface proteins of mosquito stage the malaria parasites P. falciparum vivax, respectively, are leading candidates for vaccines preventing transmission by mosquitoes. This single blinded, dose escalating, controlled Phase 1 study assessed safety immunogenicity recombinant Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion. Methodology/Principal Findings The trial was conducted at Johns Hopkins Center Immunization Research, Washington DC, USA, between...
BackgroundThe safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection United States, Chile, Peru has not been known.MethodsIn this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated safety, efficacy, immunogenicity two doses as compared with placebo preventing onset symptomatic disease 2019 (Covid-19) 15 days or more...
A controlled dengue human challenge model may determine whether to evaluate candidate vaccines in large efficacy trials.
The devil in the dengue details Along with their mosquito vectors, viruses are spreading worldwide to infect millions of people. For a few, subsequent infection results lethal hemorrhagic disease. Katzelnick et al. used antibody-binding data map structural divergence and antigenic variation among viruses. Comparing monkeys humans, approximately clustered into four known groups. However, virus groups showed as much distance within group between This finding helps explain why immune responses...
Background. The 4 serotypes of dengue virus, DENV-1–4, are the leading cause arboviral disease globally. ideal vaccine would provide protection against all after a single dose. Methods. Two randomized, placebo-controlled trials were performed with 168 flavivirus-naive adults to demonstrate safety and immunogenicity live attenuated tetravalent (TV003), compared those second an enhanced DENV-2 component (TV005), evaluate benefit booster dose at 6 months. Safety data, viremia, neutralizing...
ABSTRACT While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) humans, little is known regarding the corresponding T cell responses ZIKV. Here, we investigate kinetics and viral epitopes targeted by cells responding ZIKV address critical question of whether preexisting dengue (DENV) modulates these responses. We find that memory elicited prior infection with DENV or vaccination tetravalent attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This...
The recombinant dengue virus type-4 vaccine candidate 2AA30 was attenuated in rhesus monkeys due to an engineered 30-nucleotide deletion the 3'-untranslated region of viral genome. A clinical trial evaluate safety and immunogenicity a single dose 2Adelta30 conducted with 20 adult human volunteers. well tolerated did not cause systemic illness any Viremia detectable 14 volunteers at mean level 1.6 log10 plaque-forming units/ml serum, although all seroconverted seven-fold or greater increase...
Apical membrane antigen 1 (AMA1), a polymorphic merozoite surface protein, is leading blood-stage malaria vaccine candidate. A phase trial was conducted with 30 malaria-naive volunteers to assess the safety and immunogenicity of AMA1-C1 vaccine. contains an equal mixture recombinant proteins based on sequences from FVO 3D7 clones Plasmodium falciparum. The were expressed in Pichia pastoris adsorbed Alhydrogel. Ten each three dose groups (5 mug, 20 80 mug) vaccinated open-label study at 0,...
West Nile virions incorporate 180 envelope (E) proteins that orchestrate the process of virus entry and are primary target neutralizing antibodies. The E newly synthesized (WNV) organized into trimeric spikes composed pre-membrane (prM) protein heterodimers. During egress, immature undergo a protease-mediated cleavage prM results in reorganization pseudo-icosahedral arrangement characteristic mature virions. While is required step life cycle, complete maturation not for infectivity...
Background. Dengue virus (DENV) causes hundreds of millions infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood severe disease a second, heterotypic DENV infection. Methods. In randomized, placebo-controlled study, safety immunogenicity 4 different admixtures live attenuated tetravalent (LATV) vaccine were evaluated in 113 flavivirus-naive adults. Serum neutralizing antibody levels to all viruses measured on days 0, 28, 42, 180....
The incidence of infection with any the four dengue virus serotypes (DENV1 to -4) has increased dramatically in last few decades, and lack a treatment or vaccine contributed significant morbidity mortality worldwide. A recent comprehensive analysis human T cell response against wild-type DENV suggested an lymphocyte antigen (HLA)-linked protective role for CD8(+) cells. We have collected one-unit blood donations from study participants receiving monovalent tetravalent live attenuated (DLAV),...
Neutralizing antibodies are a significant component of the host's protective response against flavivirus infection. Neutralization flaviviruses occurs when individual virions engaged by with stoichiometry that exceeds required threshold. From this "multiple-hit" perspective, neutralizing activity is governed affinity which it binds its epitope and number times determinant displayed on surface virion. In study, we investigated time-dependent changes in fate West Nile virus (WNV) decorated...
Transmission-blocking vaccines (TBVs) that target sexual stage parasite development could be an integral part of measures for malaria elimination. Pfs25 is a leading TBV candidate, and previous studies conducted in animals demonstrated improvement its functional immunogenicity after conjugation to EPA, recombinant, detoxified ExoProtein A from Pseudomonas aeruginosa. In this report, we describe results open-label, dose-escalating Phase 1 trial assess the safety Pfs25-EPA conjugates...
The gold-standard method for quantifying neutralizing antibody responses to many viruses, including dengue virus (DENV), is the plaque reduction neutralization test (PRNT, also called immunofocus test). PRNT conducted on 96-well plates high-throughput and requires a smaller volume of antiserum than 6- or 24-well plates, but manual counting challenging existing automated counters are expensive difficult optimize. We have developed Viridot (Viridot package), program R with user interface in...
Infection caused by the four serotypes of dengue virus (DENV-1-4) is a leading cause mosquito-borne disease. Clinically-severe disease more common when secondary infection occurs following prior with heterologous serotype. Other flaviviruses such as yellow fever virus, Japanese encephalitis and Zika can also elicit antibodies which are cross-reactive to DENV. As candidate vaccines become available in endemic settings for individuals who have received other flavivirus vaccines, it important...